Derivative works — US Patent 12168036

Defensive Disclosure and Prior Art Generation

Publication Date: May 1, 2026
Subject: Derivative Works and Obvious Implementations of High-Concentration Aflibercept Formulations for Ophthalmic and Systemic Use.
Based on Analysis of: U.S. Patent 12,168,036

This document discloses a series of technical variations, applications, and integrations related to the core teachings of U.S. Patent 12,168,036 ('036 patent). The purpose is to establish prior art for foreseeable and obvious extensions, thereby precluding future patenting of these incremental improvements. The disclosures herein are described in sufficient detail to enable a Person Having Ordinary Skill in the Art (PHOSITA) to practice the inventions.

Derivative Set 1: Based on Core Claim 21 (The Formulation)

Core Claim Elements: A stable injectable aqueous formulation comprising ~114.3 mg/mL aflibercept, ~10 mM histidine buffer, ~5% (w/v) sucrose, ~0.03% (w/v) polysorbate 20, and ~50 mM L-arginine monohydrochloride, at pH ~5.8, with specified viscosity and stability.

Variation 1.1: Component Substitution - Bio-responsive Buffer System

Enabling Description: A high-concentration aflibercept formulation (80-200 mg/mL) is prepared using a dual-component, bio-responsive buffer system instead of histidine. The system consists of 15 mM sodium succinate and 15 mM Tris-HCl. At the storage pH of 5.5, the succinate component provides primary buffering. Upon injection into the vitreous (physiologic pH ~7.4), the Tris component (pKa ~8.1) becomes the dominant buffer, minimizing local pH disruption at the injection site. The formulation further includes 8% (w/v) trehalose as a lyoprotectant and cryoprotectant, and 0.05% (w/v) Poloxamer 188 (Pluronic F-68) as a surfactant, which provides shear protection during injection. This system enhances stability at storage pH while improving physiological compatibility upon administration.
```
flowchart TD
    A[Formulation in Syringe @ pH 5.5] -- Injection --> B{Vitreous Humor @ pH 7.4};
    A -- Buffering --> C[Succinate Buffer Active];
    B -- pH Shift --> D[Tris-HCl Buffer Active];
    C -- Protein Stability --> E(Aflibercept Stable in Storage);
    D -- Biocompatibility --> F(Minimized pH Shock at Injection Site);
```

Variation 1.2: Component Substitution - Alternate Viscosity-Reducing Excipient

Enabling Description: The L-arginine monohydrochloride component is replaced with a combination of 40 mM L-proline and 20 mM sodium citrate. This combination disrupts protein-protein interactions through a different mechanism than arginine, reducing the viscosity of a 150 mg/mL aflibercept solution to approximately 10 cP at 20°C. The formulation is buffered with 20 mM sodium acetate at pH 5.5 and stabilized with 4% (w/v) mannitol and 0.02% (w/v) Brij-35 (polyoxyethylene 23 lauryl ether). The use of proline and citrate avoids potential counter-ion effects associated with hydrochloride salts and offers a different impurity profile.
```
classDiagram
    class AfliberceptFormulation {
        +protein: Aflibercept(150mg/mL)
        +buffer: SodiumAcetate(20mM, pH 5.5)
        +stabilizer: Mannitol(4% w/v)
        +surfactant: Brij-35(0.02% w/v)
        +viscosityReducer1: L-Proline(40mM)
        +viscosityReducer2: SodiumCitrate(20mM)
    }
    AfliberceptFormulation --|> InjectableSolution : is a
    class InjectableSolution {
        +viscosity: ~10 cP
        +osmolality: 280-350 mOsm/kg
    }
```

Variation 1.3: Operational Parameter Expansion - Thermogelling Depot Formulation

Enabling Description: A sustained-release formulation of aflibercept (60 mg/mL) is prepared using a thermo-responsive polymer. The formulation comprises aflibercept, 10 mM phosphate buffer pH 6.2, 2% sucrose, and 22% (w/v) Poloxamer 407. This formulation is a low-viscosity liquid (< 20 cP) at refrigerated temperatures (2-8°C). Upon intravitreal injection, the formulation warms to body temperature (~37°C), causing the Poloxamer 407 to undergo a phase transition into a semi-solid gel depot. Aflibercept is then released from this depot over a period of 4-6 months via diffusion and bio-erosion of the gel, drastically reducing injection frequency.
```
stateDiagram-v2
    [*] --> Liquid_State : Stored at 2-8°C
    Liquid_State: Viscosity < 20 cP
    Liquid_State --> Gel_Depot : Intravitreal Injection (Warms to 37°C)
    Gel_Depot: Viscosity > 1000 cP
    Gel_Depot --> Released_Drug : Sustained Release (Diffusion & Erosion)
    Released_Drug --> [*]
```

Variation 1.4: Cross-Domain Application - AgTech Localized Growth Inhibition

Enabling Description: A high-concentration (100 mg/mL) formulation of a plant-derived lectin-Fc fusion protein, which binds to root-specific growth factors, is developed for agricultural applications. The formulation is based on the principles of the '036 patent, comprising 50 mM sodium acetate buffer pH 5.0, 10% (w/v) glycerol as a stabilizer and anti-freeze agent, and 0.1% (w/v) Tween 80. The formulation is designed for injection into the soil near building foundations or into the cambium of invasive tree species. The high-concentration, stable formulation ensures localized, long-term inhibition of root growth to prevent infrastructure damage, without requiring widespread herbicide application.
```
flowchart LR
    subgraph Preparation
        A(Lectin-Fc Fusion Protein)
        B(Glycerol Stabilizer)
        C(Acetate Buffer)
        D(Tween 80 Surfactant)
    end
    A & B & C & D --> E[High-Concentration Formulation];
    subgraph Application
        E -- Soil Injection --> F(Prevent Root Damage to Foundations);
        E -- Cambium Injection --> G(Inhibit Growth of Invasive Trees);
    end
```

Variation 1.5: Integration with Emerging Tech - AI-Optimized Patient-Specific Formulation

Enabling Description: An automated compounding system uses the '036 patent formulation as a base but integrates an AI-driven optimization module. Prior to preparing the injection, the system receives real-time data for the patient, including intraocular pressure (IOP), retinal thickness from an OCT scan, and biomarker levels from a tear fluid sample. A pre-trained machine learning model predicts the optimal aflibercept concentration (between 80-150 mg/mL) and L-arginine concentration (between 25-75 mM) to maximize therapeutic effect while minimizing IOP spikes for that specific patient. The system then aseptically compounds the patient-specific formulation from sterile, high-concentration stocks.
```
sequenceDiagram
    participant PatientData as Patient EHR/Sensor
    participant AI_Model as AI Optimization Engine
    participant Compounder as Robotic Compounding System
    participant Syringe as Final Patient-Specific Dose

    PatientData ->> AI_Model: Transmit IOP, OCT, Biomarker Data
    AI_Model ->> AI_Model: Calculate Optimal [Aflibercept] & [Arginine]
    AI_Model ->> Compounder: Send Formulation Parameters
    Compounder ->> Compounder: Aseptically mix stock solutions
    Compounder ->> Syringe: Fill with optimized formulation
```

Derivative Set 2: Based on Core Claim 28 (The Pre-filled Syringe)

Core Claim Elements: A pre-filled syringe containing a sterile volume of the formulation of claim 21, for intravitreal injection.

Variation 2.1: Material Substitution - Self-Lubricating, Silicon-Free Syringe

Enabling Description: The pre-filled syringe is constructed from a novel ethylene-norbornene copolymer that has been surface-grafted with hydrophilic poly(2-methacryloyloxyethyl phosphorylcholine) (PMPC) brushes. This surface treatment creates a self-lubricating, bio-inert inner barrel, eliminating the need for silicone oil lubricants, which are known to cause protein aggregation and the formation of silicone oil droplets in the eye. The plunger is made from a coated butyl rubber that is free of tungsten and other leachable heavy metals. This design enhances the stability of the high-concentration aflibercept formulation and improves patient safety.
```
graph TD
    A[Pre-filled Syringe] --> B{Barrel};
    A --> C{Plunger};
    A --> D{Needle};

    B --> B1[Material: Ethylene-Norbornene Copolymer];
    B --> B2[Inner Surface: Grafted PMPC Brushes];
    B2 --> B3(Self-Lubricating & Silicon-Free);

    C --> C1[Material: Coated Butyl Rubber];
    C1 --> C2(Tungsten-Free);
```

Variation 2.2: The "Inverse" - Safe-Fail Temperature Indicator Syringe

Enabling Description: The pre-filled syringe is co-filled with the high-concentration aflibercept formulation and a separate, immiscible droplet of a thermochromic liquid crystal (TLC) formulation. The TLC is engineered to undergo an irreversible color change from transparent to opaque white if its temperature exceeds 10°C. This provides a clear, non-reversible visual indicator that the syringe has experienced a temperature excursion and should not be used. This failure-mode indicator is passive, requires no electronics, and is integrated directly into the primary container, providing a higher degree of safety and supply chain integrity than external temperature logging labels.
```
flowchart LR
    subgraph Syringe State
        A(Aflibercept Formulation)
        B(Thermochromic Liquid Crystal Droplet)
    end
    A & B --> C{Syringe at 2-8°C};
    C --> D[TLC is Transparent - OK to Use];
    C -- Temperature > 10°C --> E{Irreversible Phase Change};
    E --> F[TLC is Opaque White - DO NOT USE];
```

Variation 2.3: Cross-Domain Application - Aerospace Autoinjector for Microgravity

Enabling Description: An autoinjector is designed for astronauts to self-administer a high-concentration formulation of an anti-sclerotic agent to counteract space-flight associated neuro-ocular syndrome (SANS). The device is based on the pre-filled syringe concept but is mechanically actuated to overcome challenges of fluid handling in microgravity. The syringe body is over-molded with a high-friction, radiation-hardened polymer for easy handling with gloves. The formulation itself is a highly concentrated protein therapeutic (e.g., 200 mg/mL) stabilized with a combination of sucrose and ectoine to withstand radiation and extreme temperature cycles experienced outside the Earth's magnetosphere.
```
classDiagram
    class MicrogravityAutoinjector {
        -proteinFormulation: HighConcentrationAntiSclerotic
        -syringe: RadiationHardenedPolymer
        -actuator: SpringLoadedMechanism
        +administerDose()
    }
    class HighConcentrationAntiSclerotic {
        +protein: 200mg/mL
        +stabilizer1: Sucrose
        +stabilizer2: Ectoine
        +buffer: Histidine
    }
    MicrogravityAutoinjector "1" *-- "1" HighConcentrationAntiSclerotic
```

Variation 2.4: Integration with Emerging Tech - Blockchain-Verified Smart Syringe

Enabling Description: Each pre-filled syringe is equipped with a passive NFC chip containing a unique cryptographic hash. This hash corresponds to a record on a private blockchain that immutably stores the entire manufacturing and supply chain history: batch numbers of aflibercept and all excipients, date of manufacture, sterility testing results, and time-stamped temperature logs from IoT sensors in the shipping container. Before administration, the clinician uses a smartphone app to scan the NFC chip. The app verifies the syringe's authenticity against the blockchain record and confirms that no temperature excursions have occurred. The act of scanning and verifying the dose is also logged as a new transaction, providing a complete, auditable "needle-to-patient" record.
```
sequenceDiagram
    participant Manufacturer
    participant Blockchain
    participant Syringe_NFC as Syringe w/ NFC
    participant Clinician_App as Clinician's App

    Manufacturer->>Blockchain: Create immutable record for syringe batch
    Manufacturer->>Syringe_NFC: Write unique hash to NFC chip
    Syringe_NFC->>Clinician_App: Clinician scans NFC
    Clinician_App->>Blockchain: Verify hash and check temperature logs
    Blockchain-->>Clinician_App: Return verification status (OK/Fail)
    Clinician_App->>Blockchain: Log administration event as new transaction
```

Combination Prior Art with Open-Source Standards

Scenario 1: Integration with HL7 FHIR Standard for Clinical Data

Enabling Description: The '036 formulation is packaged in a pre-filled syringe with a unique 2D barcode. A clinic's medication administration software, which is compliant with the HL7 FHIR (Fast Healthcare Interoperability Resources) standard, is used to manage the injection process. Upon scanning the barcode, the system creates a MedicationAdministration FHIR resource. This resource captures the specific lot number of the aflibercept formulation, the dosage administered (e.g., 8 mg), the injection site (e.g., left or right eye, identified by a SNOMED-CT code), and links to the Patient and Practitioner resources. This use of an open-source health data standard renders the integration of this or any similar formulation into standard clinical workflows obvious, creating a standardized, interoperable electronic health record of the treatment.

Scenario 2: Integration with OpenCV for Quality Control

Enabling Description: During the manufacturing of the '036 formulation, a quality control station is implemented on the filling line. The station uses a high-resolution camera and a computer vision system running the open-source OpenCV library. As each filled syringe passes, the system captures an image and applies a series of OpenCV functions: 1) cv::Canny to detect the edges of the plunger and determine the precise fill volume; 2) cv::HoughCircles to detect and count any visible particulate matter (aggregates); and 3) cv::matchTemplate to compare the overall image against a "golden standard" template. Syringes that fail any of these automated visual inspections are automatically rejected. This combination discloses the use of open-source machine vision to ensure the quality and stability parameters central to the patent's claims.

Scenario 3: Integration with GROMACS for In-Silico Formulation Screening

Enabling Description: To discover novel viscosity-reducing excipients (as in Variation 1.2), a computational screening platform is established using the open-source molecular dynamics software GROMACS. A validated molecular model of multiple aflibercept homodimers in aqueous solution is created. The system then simulates the molecular dynamics of the protein solution with the addition of hundreds of different candidate excipients from a virtual library (e.g., various amino acids, small molecule sugars, organic salts). The simulations are run on a distributed computing cluster. The resulting trajectories are analyzed to calculate the solution's simulated viscosity. This method, combining the patented formulation's core problem (viscosity) with an open-source simulation engine, makes the discovery of new excipients via computational chemistry an obvious path for a PHOSITA.